Accepted for/Published in: JMIR Research Protocols
Date Submitted: May 15, 2024
Date Accepted: Nov 8, 2024
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Mesenchymal Stem Cell Therapy for Acute Myocardial Infarction: A Protocol for Systematic Review and Meta-Analysis
ABSTRACT
Background:
Medical therapy and interventional approaches have improved outcomes in patients with acute myocardial infarction (MI). However, these strategies are inadequate for replacing cells lost during tissue ischemia, thereby leaving behind non-contractile scar tissue. The anti-inflammatory and immune modulating properties of mesenchymal stem cells (MSCs) may prove useful toward inducing functional cardiac regeneration following acute MI.
Objective:
This is a protocol for a systematic review and meta-analysis which will aggregate and synthesize high-level clinical data on the effects of MSC therapy for acute MI. The findings of this study may serve as evidence for clinicians and researchers in guiding the use of MSC therapy as an adjunct to reperfusion and optimal medical therapy in patients with acute MI.
Methods:
The proposed systematic review is registered with PROSPERO (registration number CRD42024522398). A systematic search of bibliographical databases, including Embase, Pubmed, and Cochrane was conducted from inception to June 2023 to identify English-language human studies with adult patients receiving MSC therapy and optimal medical therapy for acute MI in comparison with respective controls. Article screening will be performed using PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. Data on functional cardiac outcomes and major adverse cardiac events will be extracted and analyzed as primary outcomes.
Results:
Literature search and article screening commenced in June 2023. Data extraction and analysis will be completed by July 2024. Findings will be synthesized and reported by the end of August 2024.
Conclusions:
This systematic review and meta-analysis will summarize the best available updated evidence from published randomized controlled trials on the effects of MSC therapy for the treatment of acute MI. The findings of this systematic review and meta-analysis may shed light on the efficacy of MSC therapy toward improving cardiac functional and structural parameters and reducing adverse cardiac events following acute MI. Clinical Trial: PROSPERO registration number CRD42024522398
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.